Author: Sophia Clifton

Late-stage patients with pleural mesothelioma have survived longer than anticipated — with good quality of life — in a phase I clinical trial studying the effectiveness of a novel combination treatment. The treatment involves galinpepimut-S, the latest targeted cancer vaccine also known as GPS, in combination with Opdivo, a popular immunotherapy drug. Memorial Sloan Kettering […]

The post Novel Clinical Trial Helping Late-Stage Mesothelioma Patients appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.

Over the years, I have “collected” many families affected by the BAP1 cancer syndrome, a novel medical condition we discovered in 2011. Pathogenic germline mutations, most of them BAP1 mutations, are estimated to be found in 10% of all those diagnosed with mesothelioma. BAP1 germline mutations occur in people born with only one functioning copy […]

The post Carbone: Building the Guide to BAP1 Mutation in Mesothelioma appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.

Future treatment of pleural mesothelioma cancer continued its move toward a more personalized, targeted approach with the latest results from a multi-center clinical trial involving tazemetostat, a novel protein inhibitor. Tazemetostat, also known as the brand name Tazverik, showed impressive effectiveness in a second line setting for patients with the BAP1 genetic mutation. The disease […]

The post Targeted Therapy Making Progress with Pleural Mesothelioma appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.